Loading...
Proteolysis‐targeting chimeras in drug development: A safety perspective
Proteolysis‐targeting chimeras are a new drug modality that exploits the endogenous ubiquitin proteasome system to degrade a protein of interest for therapeutic benefit. As the first‐generation of proteolysis‐targeting chimeras have now entered clinical trials for oncology indications, it is timely...
Na minha lista:
| Udgivet i: | Br J Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7070175/ https://ncbi.nlm.nih.gov/pubmed/32022252 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.15014 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|